Clinical Trial Update: Rituximab Monotherapy for EBV-HLH and CAEBV [Phase 3]

View source ↗

Summary

Phase 3 trial update on rituximab monotherapy for EBV-associated conditions, including Secondary Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Epstein-barr Virus Infection
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection | Phase 3 | Status: UNKNOWN